🇺🇸 Methylphenidate Extended Release Capsules in United States

5 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Window: 22 April 2025 – 22 April 2026
Total reports: 5

Most-reported reactions

Abnormal Behaviour — 1 report (20%)
Confusional State — 1 report (20%)
Feeling Abnormal — 1 report (20%)
Hypersexuality — 1 report (20%)
Product Substitution Issue — 1 report (20%)

Source database →

Other Neurology; Psychiatry approved in United States

Frequently asked questions

Is Methylphenidate Extended Release Capsules approved in United States?

Methylphenidate Extended Release Capsules does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Methylphenidate Extended Release Capsules in United States?

UCB Pharma is the originator. The local marketing authorisation holder may differ — check the official source linked above.